Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KAT2A | Q92830 | 3/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15583 | 0.70 | — | — | |
| SCHEMBL6288737 | 0.68 | — | — | |
| SCHEMBL17595307 | 0.62 | CYP1A2 (0.30) | — | |
| Tetrahydrofuran SCHEMBL8329821 | 0.61 | FUCA1 (0.33) | — | |
| Iodide SCHEMBL11560630 | 0.60 | — | — | |
| SCHEMBL3774613 | 0.58 | — | — | |
| SCHEMBL6439905 | 0.56 | — | — | |
| SCHEMBL27483872 | 0.56 | NFKB1 (0.32) | — | |
| SCHEMBL10627324 | 0.56 | PPARG (0.37) | KAT2A | |
| SCHEMBL665389 | 0.56 | CYP1A2 (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0452809-B1 | A therapeutic agent for pollakiuria, urinary urgency or incontinence of urine comprising alpha-phenyl-alpha-pyridylalkanoic acid derivatives | FUJISAWA PHARMACEUTICAL CO (JP) | 1994-07-27 | — | — | EP | disclosed |
| US-5202331-A | THERAPEUTIC AGENT FOR DYSURIA COMPRISING ALPHA-PHENYL-ALPHA-PYRIDYLALKANOIC ACID DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1993-04-13 | — | — | US | disclosed |
| EP-0452809-A2 | A therapeutic agent for pollakiuria, urinary urgency or incontinence of urine comprising alpha-phenyl-alpha-pyridylalkanoic acid derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1991-10-23 | — | — | EP | disclosed |